Key result
Macitentan and selexipag cut PAH morbidity and mortality risk up to ~56% across age groups.
Why the study?
Age affects disease severity and patient outcomes in pulmonary arterial hypertension, motivating this post-hoc analysis to identify prognostic age groups and associated treatment effects of macitentan and selexipag.
Do macitentan and selexipag reduce the risk of morbidity and mortality events consistently across prognostic age groups (<35, 35-64, and >=65 years) in patients with pulmonary arterial hypertension?
RCT (n=1,648)
Double-blind
SERAPHIN: 1:1:1 to placebo, macitentan 3 mg, or macitentan 10 mg; GRIPHON: 1:1 to placebo or selexipag
Yes
Do macitentan and selexipag reduce the risk of morbidity and mortality events consistently across prognostic age groups (<35, 35-64, and >=65 years) in patients with pulmonary arterial hypertension?
In patients with pulmonary arterial hypertension, younger patients (<35 years) on placebo had a significantly higher risk of morbidity/mortality than middle-aged patients (35-64 years), and both macitentan and selexipag consistently reduced morbidity/mortality risk across all prognostic age groups.
Answers are grounded in this paper and cite their sources.
Supports macitentan and selexipag across PAH age groups; extends SERAPHIN/GRIPHON by confirming efficacy in younger high-risk patients.
BACKGROUND Age affects disease severity and patient outcomes in pulmonary arterial hypertension. This post-hoc analysis identified prognostic age groups and associated macitentan/selexipag treatment effects. METHODS Randomized trials evaluated macitentan (SERAPHIN; NCT00660179) and selexipag (GRIPHON; NCT01106014) versus placebo (primary endpoint: time to morbidity/mortality [M/M]). This analysis defined age thresholds differentiating M/M risk in patients randomized to placebo (Cox regression determining treatment effect by age). RESULTS Three age groups (< 35, 35–64, ≥ 65 years) showed good M/M risk discrimination (c-statistic 0.69, SERAPHIN; 0.66, GRIPHON). M/M risk was higher in placebo patients < 35 versus 35–64 years (SERAPHIN: hazard ratio [HR] 1.73, 95% confidence interval [CI] 1.10–2.72, p = 0.02; GRIPHON: HR 1.81, 95% CI 1.28–2.56, p < 0.001). M/M risk trended higher in patients ≥ 65 versus 35–64 years (SERAPHIN: HR 1.55, 95% CI 0.89–2.69, p = 0.12; GRIPHON (HR 1.08, 95% CI 0.75–1.55, p = 0.69). M/M risk was lower with macitentan/selexipag versus placebo: macitentan < 35 (HR 0.44, 95% CI 0.25–0.78; p = 0.005), 35–64 (HR 0.50, 95% CI 0.33–0.76; p < 0.001), ≥ 65 years (HR 0.69, 95% CI 0.30–1.58; p = 0.38); selexipag < 35 (HR 0.50, 95% CI 0.32–0.78; p = 0.002), 35–64 (HR 0.72, 95% CI 0.54–0.96; p = 0.03), ≥ 65 years (HR 0.55, 95% CI 0.33–0.91; p = 0.02). Adverse-event discontinuations were similar. CONCLUSIONS The benefit (vs placebo) of macitentan/selexipag on reducing risk of M/M events was consistent across all ages, including the younger group where significant treatment effects were observed.
No takes yet. Share an insight, caveat, or question.
Channick et al. (2025) conducted an RCT in Pulmonary arterial hypertension (n=1,648). Macitentan and selexipag vs. Placebo was evaluated on Time to first morbidity/mortality (M/M) event (evaluated across prognostic age groups <35, 35-64, and >=65 years) (HR 0.44, 95% CI 0.25-0.78, p=0.005). Macitentan and selexipag consistently reduced morbidity/mortality risk across all PAH age groups versus placebo, halving risk in patients <35 years.
Synapse has enriched 10 related papers. Consider them for comparative context: